Uptravi (Selexipag) was shown to be effective in reducing hospitalization for PAH and reducing the risks of disease progression compared to placebo. FDA, 12/22/2015. (Also see Treatments for Pulmonary Hypertension)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.